Group 1 - The company has provided a guarantee of 400 million RMB for its subsidiary Tianjin Tianshili Pharmaceutical Commercial Co., Ltd., which is a wholly-owned subsidiary of Tianshili Pharmaceutical Group Co., Ltd. [2][4] - The guarantee was approved during the company's board meeting and aims to support the financing needs of Tianshili's subsidiaries, with a total expected guarantee amount of up to 900 million RMB for the year 2025 [3][8] - The guarantee agreement with Minsheng Bank Tianjin Branch includes a maximum guarantee limit of 400 million RMB, and the credit status of the guaranteed party is reported to be good [4][5] Group 2 - The company has no overdue guarantees and the current guarantee is within the previously estimated limit [5] - The guaranteed company, Tianjin Tianshili Pharmaceutical Commercial Co., Ltd., has an asset-liability ratio exceeding 70%, which is noted as a risk factor for investors [5] - As of the announcement date, the total external guarantee amount for the company's subsidiaries is 1.35615 billion RMB, accounting for 6.81% of the company's latest audited net assets [8]

股票代码：000999 股票简称：华润三九 编号：2025—071 华润三九医药股份有限公司 关于控股子公司天士力担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为适应天士力相关下属公司业务发展需要，满足相关公司融资担保需求，经华润三九董 事会 2025 年第七次会议及 2025 年第三次临时股东会审议通过，2025 年度天士力预计为医 药商业、江苏鸿泰药业有限公司两家全资子/孙公司不超过人民币 9 亿元的银行融资授信业 务提供连带责任担保，详见《华润三九医药股份有限公司关于公司控股子公司天士力 2025 年度担保计划的公告》（2025-038）、《华润三九医药股份有限公司 2025 年第三次临时股东会 被担保人：天津天士力医药商业有限公司（以下简称"医药商业"）。上述被担保人为 华润三九医药股份有限公司（以下简称"华润三九"或"公司"）控股子公司天士力医 药集团股份有限公司（以下简称"天士力"）下属全资子公司，不存在关联担保。 本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为 40,000 万元，累计已实际为其提 ...

Core Viewpoint - The pharmaceutical industry is experiencing a phase of performance divergence, with leading companies showing positive trends while many others face significant declines in performance. Overall, the industry's performance in the first half of 2025 is not impressive, with a revenue of 1.23 trillion yuan, down 1.2% year-on-year, and a total profit of 176.69 billion yuan, down 2.8% year-on-year. However, there is a clear trend of transformation from "generic" to "innovative" drugs, with many companies emphasizing technological innovation as a key strategy for high-quality development [1][2][3]. Industry Performance - In the first half of 2025, the pharmaceutical manufacturing industry reported a revenue of 1.23 trillion yuan, a year-on-year decrease of 1.2%, and a total profit of 176.69 billion yuan, down 2.8% year-on-year [1]. - Nearly 70 listed traditional Chinese medicine companies reported positive revenue and net profit, but over half experienced a year-on-year decline in net profit [2]. Performance Divergence - There is a notable divergence in performance among pharmaceutical companies. In the first half of 2025, 10 companies reported a net profit growth exceeding 100%, with the highest being Teva Pharmaceutical at 1313%. Conversely, 6 companies saw a net profit decline exceeding 100%, with the largest drop being 702% [3]. - Key drivers for improved performance include significant sales recovery of core products, enhanced cost control, and new product acquisitions through R&D, partnerships, or mergers [3]. R&D Investment Trends - Many leading pharmaceutical companies have significantly increased their R&D investments. For instance, China Resources Sanjiu's R&D investment reached 662 million yuan in the first half of 2025, a year-on-year increase of 68.99%. Yiling Pharmaceutical invested 399 million yuan, accounting for 9.87% of its revenue [3][4]. - Sales expenses for many companies have decreased, with a total of 492 A-share pharmaceutical companies reporting sales expenses of 159.49 billion yuan, down 3.72% year-on-year [4]. Policy Support for Innovation - The Chinese government has been actively supporting the development of innovative drugs, with 210 innovative drugs and 269 innovative medical devices approved during the 14th Five-Year Plan period, showing a trend of accelerated growth [5][7]. - In the first half of 2025, the National Medical Products Administration approved 43 innovative drugs, with 40 developed by domestic companies [7]. Strategic Focus on Innovation - Innovation has become a core strategy for many pharmaceutical companies, with several firms explicitly stating their commitment to increasing innovation efforts in their 2025 semi-annual reports. For example, China Resources Sanjiu has emphasized a dual strategy of "brand + innovation" [8]. - Companies like Teva Pharmaceutical and Taiji Group are focusing on key areas and the development of innovative traditional Chinese medicine, enhancing their competitiveness in the innovative drug sector [10]. Mergers and Acquisitions - The pharmaceutical industry has seen an increase in mergers and acquisitions, particularly following the "six merger rules" introduced in September 2024. Companies like China Resources Sanjiu and Kangyuan Pharmaceutical have actively pursued acquisitions to enhance their innovative drug capabilities [12][13]. - China Resources Sanjiu's acquisition of Teva Pharmaceutical for over 6.2 billion yuan has positioned it as a major player in the innovative drug sector, with expected synergies enhancing long-term growth potential [13][15]. Future Outlook - The pharmaceutical industry is undergoing structural adjustments and is expected to maintain resilience and vitality due to factors such as an aging population and ongoing health initiatives. The shift from "single-driven" to "dual-driven" strategies, focusing on both traditional and innovative drugs, is anticipated to drive future growth [15].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 40.12 CNY [7][12]. Core Views - The company's core CHC segment performance has been under pressure due to a decrease in flu incidence and channel adjustments, but its leading brand position in the traditional Chinese medicine OTC sector remains intact, indicating potential for sustained growth through both organic and external drivers [2][12]. - The company reported a revenue of 14.81 billion CNY for the first half of 2025, a year-on-year increase of 4.99%, while the net profit attributable to the parent company was 1.815 billion CNY, a decline of 24.31% [12]. - The company completed the consolidation of Tianshili, a traditional Chinese medicine innovative drug enterprise, enhancing its competitive edge in the innovative Chinese medicine sector [12]. Financial Summary - Total revenue projections are as follows: 24,739 million CNY for 2023, 27,617 million CNY for 2024, 30,418 million CNY for 2025, 32,406 million CNY for 2026, and 34,504 million CNY for 2027, reflecting growth rates of 36.8%, 11.6%, 10.1%, 6.5%, and 6.5% respectively [5][13]. - Net profit attributable to the parent company is projected to be 2,853 million CNY for 2023, 3,368 million CNY for 2024, 3,423 million CNY for 2025, 3,818 million CNY for 2026, and 4,287 million CNY for 2027, with growth rates of 16.5%, 18.1%, 1.6%, 11.5%, and 12.3% respectively [5][13]. - The earnings per share (EPS) estimates are 1.71 CNY for 2023, 2.02 CNY for 2024, 2.06 CNY for 2025, 2.29 CNY for 2026, and 2.58 CNY for 2027 [5][13]. Market Performance - The company's stock price has shown a 52-week range of 29.25 CNY to 51.82 CNY, with a current price of 29.50 CNY [8][12]. - The total market capitalization is approximately 49,096 million CNY [8]. Business Segments - The CHC business revenue for the first half of 2025 was 6.08 billion CNY, a year-on-year decrease of 18.4%, while the prescription drug revenue was 2.78 billion CNY, reflecting a growth of 15.2% [12]. - The gross margin for the CHC business was 59.9%, down by 2.43 percentage points year-on-year, while the gross margin for prescription drugs increased by 1.89 percentage points to 49.0% [12]. Research and Development - The company continues to invest in R&D, with notable projects including a joint development project for HiCM-188, which is the first innovative drug for heart failure regeneration therapy approved for clinical use in both China and the U.S. [12]. - A collaboration with Borui Pharmaceutical for a dual-target weight loss drug BGM0504 is also underway, with the product currently in Phase III clinical trials [12].

Group 1 - On September 10, 10 listed companies repurchased their stocks [1] - Jingao Technology had the highest repurchase amount of 217 million yuan, with a total of 15.4 million shares repurchased [1] - China Resources Sanjiu repurchased stocks worth 34.55 million yuan, totaling 5.33 million shares [1] - Bairun Co. repurchased stocks amounting to 17.98 million yuan, with 820,000 shares repurchased [1]

Group 1: R&D Strategy and Focus - The company has established research institutes focusing on traditional Chinese medicine, innovative drugs, and health drugs, aligning with its strategic direction [3] - Under the "brand + innovation" strategy, the company invests significantly in R&D, with approximately 6-7 new products launched annually [3] - The three listed companies focus on key areas: China Resources Sanjiu on "3+N" core areas, Tianshili on "3+1" areas, and Kunming Pharmaceutical Group on silver-haired health [3][4] Group 2: Collaborative Development - The collaboration with Ailipu on stem cell projects targets heart failure, a major disease with high morbidity and mortality rates, indicating significant market potential [5] - The partnership with Borui Pharmaceutical on BGM0504 injection focuses on chronic diseases like diabetes and obesity, aiming to accelerate the development process [7] Group 3: Inventory and Market Position - The current channel inventory for the CHC business is approximately 3 months, indicating a healthy status [8] - The CHC business is expected to maintain resilience, with strategies in place to enhance brand influence and product offerings [9] Group 4: Integration and Empowerment - The company is implementing a "3-4-3" integration management model to stabilize and reshape its strategic direction with Kunming Pharmaceutical and Tianshili [10][11] - Future plans for prescription drugs include enhancing academic branding and optimizing sales channels, with a focus on high clinical value products [12] Group 5: Dividend Policy - The company plans to distribute a cash dividend of 4.5 yuan per 10 shares (before tax) as part of its 2025 semi-annual equity distribution plan, maintaining a dividend payout ratio of 40%-50% [13]

Core Viewpoint - The announcement details the completion of the repurchase and cancellation of restricted stocks by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., involving a total of 5,333,927 shares, which accounts for 0.319% of the company's total share capital before the repurchase, with a total repurchase fund amounting to 34,551,411.32 yuan [2][20]. Summary by Sections Repurchase and Cancellation Details - The company has completed the repurchase and cancellation of a total of 5,333,927 restricted stocks, which represents 0.319% of the total share capital prior to the repurchase [2]. - The total amount of funds used for the repurchase is 34,551,411.32 yuan, involving a total of 376 individuals [2][20]. - Following the cancellation, the company's total share capital decreased from 1,669,588,290 shares to 1,664,254,363 shares [3]. Reasons for Repurchase - The repurchase was necessitated by the termination of labor contracts with 5 original incentive recipients, retirement of 8 recipients, and 4 recipients failing to meet performance targets [4][17]. - A total of 585,985 shares were repurchased due to the termination of contracts, accounting for approximately 0.04% of the total share capital before the repurchase [17]. - Additionally, 4,747,942 shares were repurchased due to unmet conditions for the third unlocking period of the incentive plan, representing about 0.28% of the total share capital [17]. Repurchase Price and Funding - The repurchase price for the shares varied, with specific prices set for different groups of recipients based on their circumstances [18][19]. - The total repurchase funds were sourced from the company's own funds [22]. Completion and Impact - The repurchase and cancellation were confirmed by the China Securities Depository and Clearing Corporation on September 9, 2025, and the company has completed the necessary registration changes [22]. - The cancellation of the restricted stocks is in compliance with relevant laws and regulations and will not significantly impact the company's financial status or operational results [22].

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has completed the repurchase and cancellation of part of its restricted stock under the 2021 incentive plan, marking a significant milestone in the implementation of the incentive program [1][5]. Summary by Sections Incentive Plan Progress - The incentive plan was approved by the Compensation and Assessment Committee on September 15, 2021, and underwent multiple meetings and approvals before implementation [2]. - The company granted 8.24 million shares at a price of 14.84 yuan per share to 267 incentive targets on May 25, 2022, and an additional 1.206 million shares at 23.48 yuan per share to 131 targets on August 29, 2022 [2]. Repurchase and Cancellation Details - The repurchase involved 585,985 shares from 8 individuals who retired and 4 individuals who did not meet performance standards, accounting for approximately 0.04% of the company's total share capital [3]. - Additionally, 4,747,942 shares were repurchased due to unmet conditions for the third release period of the incentive plan, representing about 0.28% of the total share capital [3]. Repurchase Pricing and Financials - The repurchase price varied based on the reason for departure or performance issues, with some shares repurchased at an adjusted price of 5.7817625 yuan per share, plus interest for retirees [4]. - The total funds used for the repurchase amounted to 34,551,411.32 yuan, sourced from the company's own funds [4]. Implementation Progress - On July 8, 2025, the company announced the completion of the repurchase and cancellation process, with no creditor claims received during the public notice period [5]. - The cancellation of the restricted stock was finalized on September 9, 2025, with subsequent legal and registration procedures to follow [5].

关于部分限制性股票回购注销完成的公告 股票代码：000999 股票简称：华润三九 编号：2025—070 华润三九医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： ●华润三九医药股份有限公司（以下简称"公司"或"华润三九"）本次回购注销限制 性股票合计 533.3927 万股，占回购前公司股本总额的 0.319%，回购资金总额合计为 34,551,411.32 元，涉及人数合计 376 人。 ●中国证券登记结算有限责任公司深圳分公司确认已于 2025 年 9 月 9 日办理完成公司 部分限制性股票回购注销事宜。本次注销符合法律、行政法规、部门规章、规范性文件、公 司章程、限制性股票激励计划等相关规定。 ●本次回购注销完成后，公司总股本减少 533.3927 万股，由 1,669,588,290 股减少至 1,664,254,363 股。 华润三九分别于 2025 年 5 月 14 日、2025 年 6 月 16 日召开董事会 2025 年第八次会议、 董事会 2025 年第九次会议、监事会 2025 年第五次会议、监事会 202 ...

上海市锦天城（深圳）律师事务所 关于 华润三九医药股份有限公司 2021 年限制性股票激励计划之 限制性股票回购注销实施的 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21、22、23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于华润三九医药股份有限公司 2021 年限制性股票激励计划之 限制性股票回购注销实施的 | 声明事项 | 5 | | --- | --- | | | 正文 7 | | 一、 | 本次回购注销的批准与授权 7 | | 二、 | 本次回购注销的具体情况 13 | | 三、 | 本次回购注销的实施 15 | | 四、 | 结论意见 16 | 法律意见书 致：华润三九医药股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受华润三九医药 股份有限公司（以下简称"公司"或"华润三九"）的委托，就公司 2021 年限 制性股票激励计划（以下简称"激励计划"或"本次激励计划"）相关事宜提供 专项法律服务。 本所根据《中华人民共和国公司法》（以下简称"《公司法 ...